Skip to main content

Invitrogen to Use ProtoArray Platform in Research Collaboration with FSMA

NEW YORK, Dec. 21 (GenomeWeb News) - Invitrogen will use its ProtoArray protein microarrays in a collaboration with Families of Spinal Muscular Atrophy to identify biological targets associated with spinal muscular atrophy, the organizations said today.

 

SMA is a genetic disorder that causes a chronic deficiency in the production of the survival motor neuron (SMN) protein.

 

Invitrogen scientists will use the ProtoArray technology to screen approximately 3,000 human proteins and 5,000 yeast proteins as potential targets for SMA therapeutic intervention. The work builds upon the identification of compounds that up-regulate SMN levels in an FSMA-sponsored program at DeCode Genetics, FSMA said.

 

"We hope that the discovery and characterization of critical protein targets and their associated pathways will lead to new drug discovery avenues and ultimately to novel therapeutic approaches to treat SMA," said Jill Jarecki, research director of FSMA, in a statement.

 

The organizations said that the initial target identification stage will be followed by "further collaborative work to validate the targets and develop new compound screening assays."

 

Financial terms of the collaboration were not disclosed.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.